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Objective: To analyze determinants of success and death in multidrug-resistant tuberculo-
sis patients (MDR-TB; resistance to, at least, isoniazid and rifampicin) placed on treatment
in Bulgaria during the period September 2009 to March 2010 using logistic regression.
Results: Fifty MDR-TB patients started treatment. Male:Female ratio was 2.3:1; mean age
43 years (range: 18–77); 19 patients (38%) were new; median duration of disease before
treatment was 5 years (range: 1–13). All patients tested negative for HIV. Eight cases had
XDR-TB (MDR-TB plus resistance to any fluoroquinolone and any second-line injectable).
Twenty-four months after starting treatment, 24 patients (48%) had a successful outcome,
in 6 (12%) treatment failed, 19 (38%) died, and one (2%) interrupted treatment. XDR-TB cases
experienced higher mortality than others (75% vs. 30.9%, respectively, P < 0.05). Sputum
smear positivity at start of treatment and weight loss or no weight gain were positively
associated with death (adjusted Odds ratio: 5.16; 95% confidence interval: 1.16–22.84 and
5.61; 1.48–21.20, respectively) and negatively with success (0.13; 0.02–0.94 and 0.02; 0.00–
0.19). No previous TB treatment increased likelihood of success (7.82; 1.09–56.15).
Discussion and conclusions: Most MDR-TB patients in this first treatment cohort using WHO-
recommended norms had advanced disease explaining the high mortality and low success.
Early, adequate treatment of MDR-TB patients can improve outcomes and avert
transmission.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.ov’’ Blvd.,
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Tuberculosis (TB) resistant to, at least, both isoniazid and
rifampicin (multidrug-resistant tuberculosis; MDR-TB) and
extensively drug-resistant tuberculosis (MDR-TB plus resis-
tance to any fluoroquinolone and any second-line injectable
drug; XDR-TB) represent a global public health problem [1].
The treatment of MDR-TB is longer than that for drug-sus-
ceptible TB and requires the use of at least four second-line
anti-TB drugs (SLD) likely to be effective, including a par-
enteral agent, as well as pyrazinamide, during the intensive
phase [2]. SLDs are more costly, generate more adverse
events, and are less effective than the first-line drugs (FLD).
The programmatic management of MDR-TB requires substan-
tial financial and human resources for diagnosis and treat-
ment and therefore needs to have a dedicated place in the
TB control programme [3].
The results of treatment and data on the predictors of poor
treatment outcome and mortality of MDR-TB patients have
varied among different studies and reports [4–7].
Bulgaria, a member of the European Union since 2007,
belongs to the 18 high priority countries in the World Health
Organization (WHO) European Region [8], and to the 27 high
MDR-TB burden countries worldwide [1].
Since 2007, the implementation of the National TB
Prevention and Control Programme (NTP) in Bulgaria has
been coordinated by the Department for Management of
Specialized Donor-Funded Programmes at the Ministry of
Health (Central TB Unit). A major achievement in 2008 was
the establishment of a National TB Register to collect and
report case-based TB data according to the requirements of
the European Centre for Disease Prevention and Control
(ECDC)/WHO data collection system. The system for routine
TB surveillance, which feeds into the National TB Register,
is organized around the key partnerships with following
major public health institutions throughout the country that
provide TB diagnosis and treatment: 29 Regional TB Health
Facilities responsible for TB prevention and control in all 28
administrative districts (Regional TB Units), designated with
an Order of the Minister of Health; 28 Regional Health
Inspectorates responsible for prevention and control of the
communicable diseases; 13 prisons and 2 prison hospitals
under the subordination of the Ministry of Justice; the
Military Medical Academy under the subordination of the
Ministry of Defence; the National TB Reference Laboratory
(NRL-TB) at the National Centre of Infectious and Parasitic
Diseases (NCIPD); and 33 public microbiological laboratories
at the Regional TB Units (n = 29), 3 Hospitals for Prolonged
Treatment of TB and Lung Diseases, and one State
Psychiatric Hospital for treatment of cases with TB co-mor-
bidity (Peripheral TB Units). The data flow includes the quar-
terly reporting of case-based demographic, clinical and
laboratory information about the registered TB cases and
their treatment outcome, including MDR/XDR-TB cases, by
the Regional TB Units to the Central TB Unit, responsible for
collecting, summarizing and analyzing data obtained through
the routine TB surveillance.
In 2011, Bulgaria notified 2407 TB cases, a rate of about
33 TB cases per 100,000 population. Among new sputumsmear-positive TB cases who started treatment in 2010, 86%
had treatment success, 8% died and in 2% treatment failed;
outcomes among previously treated cases were less favorable,
with 63% success, 13% death and 6% treatment failure [1].
Before 2009, MDR-TB patients in Bulgaria had been treated
with fluoroquinolones and second-line injectable drugs, but
not with regimens complying with international standards.
No case of XDR-TB had been documented before 2010 because
of the lack of capacity for Drug Susceptibility Testing (DST) to
SLD. From 2007 to 2010, a cumulative total of 206 individual
MDR-TB cases had been confirmed. All 31 MDR-TB cases
who started treatment in 2008 registered a success rate of
22.6%, with 38.7% deaths, 9.7% treatment failures and 29%
still on treatment [8].
Since 2007, the Bulgarian Government has included in the
NTP a special focus on MDR-TB and XDR-TB. The first
national specialized ward for in-patient treatment and care
of MDR-TB patients was established in a hospital specialized
for the treatment of lung diseases in Gabrovo (see Fig. 1). The
model of care for MDR-TB patients was mixed: hospital care
during the intensive phase of treatment and outpatient care
during the continuation phase.
All laboratory tests were performed by the National
Tuberculosis Reference Laboratory (NRL-TB) and the labo-
ratories in all regional TB health facilities according to WHO
recommendations [9]. The NRL-TB received the certificate by
the WHO Supranational TB Reference Laboratory (SRL) in
Italy, for DST to FLD in 2007 and 2010, and for DST to SLD in
2011. All peripheral laboratories were quality-assured twice
yearly by NRL-TB for microscopy since 2006, and for cultures
since 2010.
In 2009, following intensive preparations of policies, lab-
oratory and hospital facilities supported by the Global Fund
to Fight AIDS, Tuberculosis and Malaria (TGF), the Ministry of
Health in Bulgaria successfully started its first cohort of MDR-
TB patients on treatment using quality-assured drugs and
methods based on WHO recommendations [2,3]. In this paper,
the outcomes of the MDR-TB patients starting treatment
between September 2009 and March 2010 are reported and
the factors associated with their treatment results are studied.
Materials and methods
The data for the MDR-TB cases starting treatment during the
period September 2009–March 2010 were obtained from the
patient medical records held at the Hospital for Lung
Diseases in Gabrovo, in central Bulgaria, as well as the TB reg-
isters of the NRL-TB at the NCIPD in Sofia. The essential
demographic, clinical and microbiological data were entered
on an electronic database.
The definitions used in this study for case registration,
sputum-smear microscopy and culture, and treatment out-
comes of the cases with MDR-TB and XDR-TB conformed to
those recommended by the WHO [3,10].
Patient treatment
The MDR-TB patients described in this study were placed on
an individualized regimen composed of an initial phase
Fig. 1 – Distribution of cases with multidrug-resistant tuberculosis (n = 50) starting treatment with second-line anti-
tuberculosis drugs for the period September 2009–March 2010 by districts in Bulgaria.
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of 6 months and at least 4 months after culture conversion,
followed by a longer continuation phase which lasted for
12 months after the initial culture conversion. The com-
position of the regimens included combinations of the follow-
ing drugs: pyrazinamide, ethambutol (in cases with
confirmed sensitivity to the drug), an injectable agent (kana-
mycin or capreomycin), levofloxacin, and prothionamide, p-
amino salicylic acid and cycloserine. Regimens were modified
based on the history of drugs previously taken by the patient.
The aim was to administer at least four drugs with either cer-
tain or almost certain effectiveness, as well as pyrazinamide.
Drug dosages were modified according to body weight. All the
drugs for treatment of MDR/XDR-cases and for treatment of
adverse drug effects were free of charge for the patients.
The patients were hospitalized for a different period at the
start of the second-line therapy. All doses received in hospital
and in the ambulatory were given under direct observation
(DOT). During the continuation phase, DOT was organized
through a national network of regional TB managers and
patronage nurses, primary health care staff (general practi-
tioners, nurses and medical specialists) for patients living in
the remote areas, and NGO representatives working with
groups at risk of TB. In order to encourage adherence to treat-
ment, food vouchers were handed to MDR-TB patients during
the full course of treatment, when they presented for their
treatment encounters.
Laboratory tests
Smears for acid-fast bacilli (AFB) were examined by Ziehl-
Neelsen staining. All cultures were carried out with conven-
tional Lo¨wenstein–Jensen solid media and by liquid mediausing BACTEC MGIT960 automated system. DST of the
strains was performed in the NRL-TB by applying the refer-
ence BACTEC MGIT960 automated system following the
recommendations provided by the manufacturer (Becton
Dickinson, NJ, USA). DST to FLDs was performed using the
commercial SIRE kit for FLDs with critical concentration of
the drugs as follows: streptomycin – 1.0 lg/ml; isoniazid –
0.1 lg/ml; rifampicin – 1.0 lg/ml; ethambutol – 5 lg/ml.
Isolated strains with resistance to isoniazid or rifampicin
from 47 MDR-TB patients (out of all 50 patients starting treat-
ment) were tested against SLDs. DST to SLDs was performed
by BACTEC MGIT960 with critical concentration of the drugs
as follows: amikacin – 1.0 lg/ml; kanamycin – 5.0 lg/ml;
capreomycin – 2.5 lg/ml; and ofloxacin – 2.0 lg/ml.
Sputum-smear microscopies and cultures were conducted
on a monthly basis to monitor the response to treatment in
the laboratory in Gabrovo hospital during the intensive phase
of treatment, and in the respective laboratories at the regional
TB health facilities during the continuation (ambulatory)
phase.
HIV-ELISA tests were used to determine HIV-status at the
beginning of treatment.
Statistical analyses
Student t-test was performed to compare continuous vari-
ables between different subpopulations. Bivariate analysis
was used to explore independent associations between sev-
eral factors and treatment outcomes (success and death); a
P-value smaller than 0.05 was considered to represent a sta-
tistically significant association. A multivariable analysis
was performed to model the determinants of success and
death in logistic regression equations, using only variables
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bivariate analysis. All analyses were performed using R [11].
Ethical issues
The cases with MDR/XDR-TB included in this cohort were
treated under standard conditions of patient care in the
Republic of Bulgaria, that the treatment was not of an experi-
mental nature and that it conformed to the treatment com-
position, duration and major ethical considerations
associated with TB as recommended by WHO [2,3,12]. All
the patients completed informed consent forms for the treat-
ment with SLDs and that all measures were taken to ensure
that patient confidentiality was guaranteed when the data
were being used for this analysis (available at the hospital
in Gabrovo).
Results
A total of 50 patients with MDR/XDR-TB (42 MDR-TB and 8
XDR-TB cases) confirmed by the NRL-TB started treatment
with a second-line drug regimen during the period
September 2009–March 2010. These patients originated from
all over the country, with higher numbers from the larger con-
urbations in the capital Sofia city, Plovdiv and Varna, and
from the northwestern part of the country – in the districts
with higher than the average TB incidence in Bulgaria:
Montana, Vidin, Vratsa (Fig. 1).
The mean age was 42.8 years (range, 18–77). The
Male:Female ratio was 2.3:1. The patients were distributed
by sex and age, as follows: 5 cases (4 males and 1 female) in
age group 15–24 years, 8 cases (5 males and 3 females) in
age group 25–34 years, 16 cases (10 males and 6 females)
in age group 35–44 years, 15 cases (11 males and 4 females)
in age group 45–54 years, 3 males in age group 55–64 years,
and 3 cases (2 males and 1 female) in age group over 65 years.
Thirty-one patients had been previously treated for TB.
Median duration of disease was 5 years (range, 1–13; inter-
quartile range: 3–6).
Although a larger proportion of the 8 XDR-TB cases had
been previously treated compared with other MDR-TB casesTable 1 – Previous history of TB treatment in all cases with multi
resistant tuberculosis starting treatment with second-line anti-t
March 2010.
Previous history
New
Relapses
Treatment after interruption
Treatment after failure of initial treatment with first-line anti-T
Treatment after failure of retreatment with first-line anti-TB dr
Other
TB = tuberculosis.
MDR-TB = multidrug-resistant tuberculosis (with resistance to, at least, b
XDR-TB = extensively drug-resistant tuberculosis (multidrug-resistant tub
three injectable second-line drugs: capreomycin, kanamycin, amikacin).(Table 1), 2 patients (male 21 years old, and female 44 years
old) reported no history of prior treatment.
Forty-nine patients had pulmonary TB, and 1 patient had
extrapulmonary TB (dermatological form with bacteriological
confirmation from wound exudate). Positive smears for AFB
at treatment initiation were observed in 31 patients.
All patients were tested for HIV at the beginning of treat-
ment, and none of them had a positive result.
The mean patient body weight at treatment initiation was
56.4 kg (range: 31–79), but was lower in XDR-TB patients com-
pared with other MDR-TB patients (mean: 49.4 kg vs. 57.6 kg,
respectively; P = 0.01).
Drug resistance patterns
Out of the 50 MDR/XDR-TB cases, 24 had strains with addi-
tional resistance to streptomycin and ethambutol, 11 to iso-
niazid and rifampicin only, and the rest were resistant to
either ethambutol (6 cases) or streptomycin (9 cases).
Second-line drug susceptibility testing was performed on 47
cases: 32 cases were susceptible to amikacin, kanamycin,
capreomycin and ofloxacin; 4 cases were resistant to
ofloxacin only; and 3 cases were resistant only to all three
second-line injectable drugs. Eight cases were with XDR-TB.
More of the XDR-TB cases were female than male (5 vs. 3,
respectively).
Treatment and outcomes
The patients received a mean of 6.2 drugs (median 6, range
5–7). The median duration of hospitalization was 245 days.
Three XDR-TB patients received linezolid, 5 had co-amoxy-
clav and 2 had levofloxacin switched to moxifloxacin.
Surgical resection was performed on only 1 patient (female
36 years old) – an XDR-TB case who failed to convert to culture
negative.
By 24 months after the start of treatment, 24 MDR/XDR-TB
patients completed it successfully, 16 being bacteriologically
cured and 8 without evidence of cure. Six patients sustained
a treatment failure, 19 died and one patient interrupted
treatment.drug-resistant tuberculosis and cases with extensively drug-
uberculosis drugs in Bulgaria for the period September 2009–
MDR-TB cases
only
N = 42
XDR-TB cases
only
N = 8
All MDR/XDR-TB
cases
N = 50
17 2 19
12 0 12
9 1 10
B drugs 3 3 6
ugs 1 1 2
0 1 1
oth isoniazid and rifampicin).
erculosis with resistance to any fluoroquinolone, and at least one of
Table 2 – Treatment outcomes in cases with extensively drug-resistant tuberculosis and non-extensively drug-resistant
tuberculosis among cases with multidrug-resistant tuberculosis (n = 50) starting treatment with second-line anti-
tuberculosis drugs in Bulgaria for the period September 2009–March 2010.
Outcomes Non-XDR-TB cases
N = 42
XDR-TB cases
N = 8
MDR/XDR-TB cases
N = 50
Cured 16 0 16
Completed 8 0 8
Treatment failed 4 2 6
Died 13 6 19
Interrupted 1 0 1
TB = tuberculosis.
MDR-TB = multidrug-resistant tuberculosis (with resistance to, at least, both isoniazid and rifampicin).
XDR-TB = extensively drug-resistant tuberculosis (multidrug-resistant tuberculosis with resistance to any fluoroquinolone, and at least one of
three injectable second-line drugs: capreomycin, kanamycin, amikacin).
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cessfully (Table 2), and neither did other patients with resis-
tance to ofloxacin (N = 4) or second-line injectable drugs
only (N = 3). Among the patients in whom treatment failed
(all had been previously treated), 2 had XDR-TB, 3 had resis-
tance to ofloxacin and 1 had resistance to all injectable drugs.
One of the patients with resistance to ofloxacin stopped the
therapy because of advanced laryngeal carcinoma. Death
was higher in XDR-TB patients than in other MDR-TB patients
(Odds Ratio: 5.36, 95%CI Fisher’s exact: 0.79–58.97; P < 0.05).
Most deaths (17/19) were considered to be related to TB.
XDR-TB patients on average experienced a decrease in
body weight during treatment, while the rest of the MDR-TB
patients had an increase (means: 3.88 kg vs.+2.42 kg, respec-
tively; P = 0.001).
Determinants of treatment success and death
Determinants of success and death were explored using the
demographic, clinical and bacteriological variables available
(Tables 3 and 4). At bivariate analysis, no associations with
success or death were observed for any specific drug includedTable 3 – Associations between treatment success (vs. all other
multivariable analysis, in cases with multidrug/extensively dru
second-line anti-tuberculosis drugs in Bulgaria for the period S
Characteristic B
C
Age <30 years R
Age 30–39 years 0
Age 40–49 years 0
Age >49 years 1
Male sex 0
No previous TB treatment 2
Sputum smear positive at start of treatment 0
XDR-TB –
Weight loss or no weight gain 0
Hospitalization <180 days 0
TB = tuberculosis.
MDR-TB = multidrug-resistant tuberculosis (with resistance to, at least, b
XDR-TB = extensively drug-resistant tuberculosis (multidrug-resistant tub
three injectable second-line drugs: capreomycin, kanamycin, amikacin).
OR = Odds Ratio.
95% CLs = 95% confidence limits (binomial).in the treatment regimen. Duration of TB disease among pre-
viously treated patients was not associated with success
(median 4.5 years [IQR:2.75–6.5] in successful vs. 5 years
[IQR: 3.0–6.0] in non-successful) or death (median 5.0 years
[IQR:3–7] in those who died vs. 4.5 years [IQR: 2–6] in those
who did not die). Statistically-significant, negative associa-
tions with treatment success were observed when sputum
smear was positive at the start of treatment and when there
was weight loss or no weight gain. The same negative
associations were observed when multivariable logistic
regression analysis was performed; in addition, treatment
success was positively associated with no previous history
of TB treatment. Conversely, sputum smear positivity at start
of treatment and weight loss or no weight gain were posi-
tively associated with death at both bivariate and multivari-
able analysis.
Discussion and conclusions
This is the first study in Bulgaria assessing the treatment out-
comes of MDR-TB patients treated with drug regimens in
accordance with WHO requirements, international standardsoutcomes) and patient characteristics, bivariate and
g-resistant tuberculosis (n = 50) starting treatment with
eptember 2009–March 2010.
ivariate analysis Multivariable analysis
rude OR (95% CLs) Adjusted OR (95% CLs)
ef. Ref.
.13 (0.02–1.09) 0.05 (0.00–1.05)
.53 (0.10–2.98) 0.23 (0.02–3.14)
.67 (0.40–6.98) 2.28 (0.16–31.81)
.74 (0.22–2.48) –
.71 (0.83–8.83) 7.82 (1.09–56.15)
.25 (0.08–0.86) 0.13 (0.02–0.94)
–
.10 (0.03–0.36) 0.02 (0.00–0.19)
.66 (0.20–2.15) –
oth isoniazid and rifampicin).
erculosis with resistance to any fluoroquinolone, and at least one of
Table 4 – Associations between death (vs. all other outcomes) and patient characteristics, bivariate and multivariable
analysis, in MDR-TB cases with multidrug/extensively drug-resistant tuberculosis (n = 50) starting treatment with second-
line anti-tuberculosis drugs in Bulgaria for the period September 2009–March 2010.
Characteristic Bivariate analysis Multivariable analysis
Crude OR (95% CLs) Adjusted OR (95% CLs)
Age <30 years Ref. Ref.
Age 30–39 years 5.24 (0.70–39.48 –
Age 40–49 years 2.10 (0.32–13.61) –
Age >49 years 1.2 (0.17–8.66) –
Male sex 1.5 (0.42–5.32) –
No previous TB treatment 0.81 (0.25–2.61) 1.17 (0.30–4.64)
Sputum smear positive at start of treatment 4.0 (1.08–14.81) 5.16 (1.16–22.84)
XDR-TB 1.11 (0.41–2.98) –
Weight loss or no weight gain 4.67 (1.38–15.82) 5.61 (1.48–21.20)
Hospitalization <180 days 1.56 (0.47–5.10) –
TB = tuberculosis.
MDR-TB = multidrug-resistant tuberculosis (with resistance to, at least, both isoniazid and rifampicin).
XDR-TB = extensively drug-resistant tuberculosis (multidrug-resistant tuberculosis with resistance to any fluoroquinolone, and at least one of
three injectable second-line drugs: capreomycin, kanamycin, amikacin).
OR = Odds Ratio.
95% CLs = 95% confidence limits (binomial).
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of the first cohort of laboratory-confirmed MDR-TB cases who
started treatment in 2009–2010, of which most had longstand-
ing disease, had received anti-TB treatment in the past and of
which 16% were infected with XDR-TB strains. Only 48% fin-
ished their treatment successfully and 38% died.
Sputum smear positivity at the start of treatment and
weight loss or no weight gain were found to be the strongest
predictors for successful or lethal outcomes of treatment in
this cohort. These associations point to more advanced lung
lesions and widespread disease among the average patient,
becoming refractory even to treatment with regimens com-
posed of good-quality medicines. Otherwise, the TB patients
from this first MDR-TB treatment cohort were younger on
average (mean age 42.8 years) when compared with the rest
of the registered TB patients in Bulgaria (mean age of new
TB cases, nationals – 45.3 years in 2009 and 44 years in
2010). The Male:Female ratio (2.3:1 on average) was similar
to the sex ratio (M:F) of all TB cases registered in the country
in 2009 and 2010 (1.8:1 and 1.9:1, respectively) [8,13].
The success ratio in this MDR-TB patient group is lower
than the world average for MDR-TB patients put on treatment
in 2009 (38% vs. 48% overall), although it is likely that the pro-
portion of XDR-TB patients in this cohort (16%) was much
higher than in the global average [1]. When excluding cases
with XDR-TB, the success ratio in the Bulgarian cohort (57%)
was comparable to those in the studies reviewed by Ahuja
et al. (54% overall) [4], Johnston et al. (62%; XDR-TB cases
included) [5], and Orenstein et al. (64% for the patients receiv-
ing individualized treatment regimens and 54% for those
receiving standardized regimens; exclusive XDR-TB cohorts
not included) [6]. Similar to the findings of a recent meta-
analysis [14], the likelihood of treatment success was higher
in MDR-TB patients infected with strains without additional
resistance (N = 32, 69% success) than in those with additional
resistance to ofloxacin only, a second-line injectable drug
only, or both, i.e., XDR-TB, none of which had a successful
outcome.Treatment outcome results for XDR-TB cases showed
lower success and higher mortality than those reported in
the review from Jacobson et al. [15], although numbers were
small. Most of the Bulgarian patients with XDR-TB had long-
standing disease and had received anti-TB treatment in the
past, including second-line drugs, but not as part of the
recommended regimens. The advanced nature of disease
explains why they experienced unfavorable treatment out-
comes (death and treatment failure) in this cohort.
Adjunctive surgical resection has been reported to improve
outcomes in patients with drug-resistant TB [16–18]. Only one
patient who had localized disease with adequate pulmonary
function underwent lung resectional surgery in this series,
without successful outcome. The patient was previously trea-
ted (2 years’ duration of recorded disease), with resistance to
streptomycin and ethambutol, in addition to XDR-TB, and ini-
tially refused linezolid to be included in the treatment
regimen.
It is important that measures are taken to avert the devel-
opment of drug-resistance and to treat drug-resistant TB
more effectively. Previous treatment for TB is one of the con-
sistent and strongest risk factors for development of MDR-TB
[5,7]. Interruption of treatment is to be avoided. In 2010, 3% of
new sputum-smear positive TB patients and 12% of retreated
TB patients in Bulgaria interrupted their treatment [1]. TB
patients on first-line regimens for drug-susceptible disease
are to be supported to ensure good adherence and thus
reduce the risk of emergence of MDR-TB. It is also worth high-
lighting, however, that 38% of cases from the current cohort –
including 2 with XDR-TB – gave no history of previous use of
anti-TB drugs. This in itself is a cause for concern as it sug-
gests deficiencies in infection control with active transmis-
sion of drug-resistant strains – a risk to be expected when
patients do not have access to timely diagnosis and appropri-
ate treatment. The nationwide distribution of both MDR-TB
and XDR-TB cases signifies that preventive measures need
to have a country-wide span. From 2011 to date, another
100 MDR-TB cases confirmed by the NRL-TB in Bulgaria
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recommended norms and through the support of TGF. There
are no MDR-TB patients on the waiting list.
Some limitations to this analysis are pointed out. As this
was a retrospective study, most information was obtained
from medical records, which limited the choice of predictors
of treatment outcomes and survival. For example, not all
information on previous TB treatment could be obtained from
all patients, especially when the previous episode was
remote. The small number of cases precluded this analysis
from achieving statistical significance on a number of
associations with other variables: contact with index case,
duration of the previous treatment with first- and second-line
drugs, time for microbiological conversion, and the presence
of XDR-TB, a sub-group of patients that had very poor out-
comes in particular.
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